DAIICHI SANKYO, INC.

Over 20 drugmakers from Japan, the U.S., and Europe, including Eisai, Amgen, and Novartis, launched a $1 billion+ fund to support startups tackling antibiotic-resistant infections, with WHO and European Investment Bank participation.

A multicenter retrospective analysis evaluated combination systemic therapies in 253 nccRCC patients from 2012-2024. Results showed limited antitumor activity, with differential responses among nccRCC subsets based on regimen type. Optimal nccRCC management remains an unmet need, highlighting the necessity for further research.

LEAP-012 trial showed len + pembro + TACE significantly improved PFS vs placebo + TACE in intermediate-stage HCC patients. OS data were immature, with a trend toward improvement. Safety profiles were consistent with known effects of the treatments. OS will be reassessed in future analyses.